Evaluation of the Clinical Performance of the PremaSure Kit to Assess Premature Delivery Risk in Symptomatic Pregnant Patients

The goal of the study is to determine the clinical performance of the PremaSure kit, more precisely to assess whether the PremaSure kit can be used as a self-test to assess the risk of premature delivery in patients showing symptoms of premature delivery. The sensitivity and specificity of the test will be determined using as an outcome the delivery of the patient in the 7/14 days following the test.

The simplified procedure is the following:

1. Patients are recruited and screened for eligibility criteria
2. A healthcare professional collects a vaginal swab from the patient
3. The collected sample is tested on the PremaSure kit
4. Pregnancy outcome is compared to the PremaSure kit's result

Study Overview

• Status: Recruiting
• Conditions: Preterm Delivery

Detailed Description

Introduction:

Preterm birth is the first cause of death of infants below five years old. One of the key strategies to save preterm babies is to effectively identify women at risk of preterm birth. While current solutions for the assessment of prematurity risk rely on invasive examination performed by medical professional, the PremaSure is intended to be used by lay user, empowering them with a tool to monitor their pregnancy.

Measurement and procedures:

Consenting patient meeting all the inclusion and none of the exclusion critera will be swabbed by a healthcare professional to collect vaginal secretions. A study nurse will perform the test per the test's IFU. Information related to the patient's delivery will be collected after term to evaluate the predictive performance of the PremaSure kit.

Withdrawal and discontinuation:

Participants can withdraw their consent from the study at any time with no consequence for their clinical management. Patients do not have to provide any reason for withdrawing their consent. Patients who wish to withdraw consent for participation in the study, must notify the Principal Investigator by sending an email to or calling the Principal Investigator using the email address/ phone number mentioned in the ICF. Upon receipt of a notification that a patient wishes to withdraw from the study, the Principal Investigator will document the withdrawal in the eCRF and inquire whether the patient consents that already collected data can be kept on record.

Labelling of the device under investigation:

As the IVD device is not commercially available, the labelling shall indicate that the IVD device under investigation is exclusively for use in a performance study. Each device will have a unique identifying number to trace its origin and manufacturing lot.

Accountability of the IVD device:

Upon receipt at the study sites, the kits shall be stored in a secured location and only accessible for team members involved in the study.

Unused, expired or malfunctioning IVD devices shall be returned to the sponsor.

Monitoring plan:

For each of the sub-studies, a separate site initiation visit will be performed after all required approvals are obtained. As part of this visit the staff involved in the study at the study site will be trained on the procedures presented in this protocol. The devices/kits will be shipped to the site after authorization of the study by the Ethics Committee and approval of the required essential documents.

During the study, the monitor will contact and visit the site regularly. The monitor must have access, with reasonable prior notice, to the facilities of the study site and all source documents needed to verify adherence to the protocol as well as the completeness, consistency and accuracy of the data being entered on the eCRFs and other protocol-related documents. Additional checks of the consistency of the source data with the eCRFs will be performed according to the study-specific monitoring plan. The frequency of the monitoring visits will be mainly based on subject recruitment.

The investigator/delegate must ensure that the eCRFs are completed per the eCRF completion guidelines and that all requested subject files (e.g., ICF, medical notes/charts, other documentation verifying the activities conducted at the study) are available for review by the monitor. The required site staff must be available during the monitoring visits and allow necessary time to meet with the monitor to discuss study-related topics and issues.

A close-out visit will be performed for any initiated site.

Data recording:

Electronic Data Capture (EDC) will be used to collect eCRF data. The eCRF, based on RedCap solution, must be completed in a timely manner as per the eCRF completion guidelines.

The principal investigator and delegate site staff member(s) will be trained to enter and edit the data via a secure network, with secure access features (username, password and identification). While entering the data, the principal investigator/delegate will be instantly alerted to data queries by validated programmed checks. Additional review will be performed by the sponsor/monitor on an ongoing basis to check for unexpected patterns in data and for study monitoring. Should discrepant data be detected, a manual query will be issued for clarification of the data. The query will be visible to the principal investigator/delegate via the eCRF. Response/correction by the principal investigator/delegate will be performed directly in the eCRF. All eCRF entered data require must have documented background data which will remain available for the monitor and to health authorities queries and inspections. A complete electronic audit trail will be maintained in the EDC system. The investigator/delegate will approve the data, confirming its accuracy and completion by signing the eCRF electronically (as per US 21 CFR part 11). Data will be stored on secured servers in Switzerland.

Source data verification will be performed by the monitor. In the electronic database the sponsor shall have access to coded data that can be used to monitor patient recruitment and endpoint assessment.

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

• Study Contact: Name: Pierre-Emmanuel Thiriet, PhD; Phone Number: +41216931345; Email: pierre-emmanuel.thiriet@readiagnostics.com

Study Locations

• Switzerland
  • Canton of Vaud
    • Lausanne, Canton of Vaud, Switzerland, 1001
      • Recruiting
      • Centre Hospitalier Universtaire Vaudois (CHUV)
      • Contact: David Baud, PhD; Phone Number: +41213143953; Email: david.baud@chuv.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Pregnant patients with symptoms of premature delivery.

Description

Inclusion Criteria:

• Informed Consent signed by the subject
• Female patients above 18 years
• Gestational week from 22w+0 days to 35w+6 days
• Symptoms of prematurity.

Exclusion Criteria:

• Subject lacking capacity to provide informed consent
• Enrolment of the project leader, their family members, employees and other dependent persons
• Patients with ruptured amniotic membranes or blood in their vaginal discharge
• Patients with vaginal examination in the last 24 hours
• Previous enrolment in the current study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the clinical performance of the PremaSure kit	On the population of patients who have fully completed the study without experiencing a non-spontaneous delivery up to 14 days after the sample collection, we will determine the sensitivity, specificity, accuracy, positive and negative predictive values (PPV and NPV respectively) of the PremaSure test for the identification of pregnant women at risk of pre-term delivery at 7 and 14 days, respectively	From enrollment to the delivery of the patient

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Estimation of the clinical performance of the PremaSure kit on sub-group population	Estimation of sensitivity and specificity, PPV, NPV and prevalence for the risk of pre-term delivery of sub-groups, defined as any combination of the categories derived from the pregnancy information collected in the context of the present study. The statistical study power may not be attained for each subgroup. The aforementioned values will be determined considering as an outcome a delivery at 7 days, 14 days, or at any duration following the test.	From enrollment until the delivery of the patient
Estimation of correlation coefficients between the participant pregnancy information and the outcome of the pregnancy		From enrollment until delivery of the patient.

Collaborators and Investigators

• Sponsor: Rea Diagnostics SA
• Collaborators: Centre Hospitalier Universitaire Vaudois

Study record dates

Study Major Dates

• Study Start (Actual): December 5, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027

Study Registration Dates

• First Submitted: December 15, 2025
• First Submitted That Met QC Criteria: December 15, 2025
• First Posted (Actual): December 29, 2025

Study Record Updates

• Last Update Posted (Actual): December 29, 2025
• Last Update Submitted That Met QC Criteria: December 15, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Preterm Delivery; Self-test
• Additional Relevant MeSH Terms: Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications; Premature Birth
• Other Study ID Numbers: REA-2024-02260

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No